HEC 88473
Alternative Names: HEC-88473Latest Information Update: 28 Jun 2024
At a glance
- Originator Dongguan HEC TaiGen Biopharmaceuticals
- Developer Dongguan HEC TaiGen Biopharmaceuticals; HEC Pharm
- Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Type 2 diabetes mellitus
- Phase I/II Non-alcoholic steatohepatitis
- Phase I Obesity
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis(In volunteers) in Australia (SC, Injection)
- 28 Dec 2023 Phase-I/II clinical trials in Non-alcoholic steatohepatitis in China (SC) Prior to December 2023 (CTR20211088)
- 28 Nov 2023 Phase-II clinical trials in Type 2 diabetes mellitus in China (SC) (NCT06148649)